Antimicrobial Stewardship Pearls to Optimize Patient Outcomes: Matthew B. Goetz, MD
May 19th 2022“Clearly, stewardship is a team operation. It starts [with] the leadership, the clinical pharmacy, and coordination with infectious disease physicians truly has to be synergistic,” Goetz said in the keynote address at MAD-ID 2022.
Watch
Researchers Document Longest Known COVID-19 Infection, Occult Infection
April 27th 2022Lasting 505 days, investigators documented the longest known COVID-19 infection. The research, presented at ECCMID, also found one of the first cases of occult COVID-19, in which a patient who tests negative is later found to have ongoing COVID-19.
Read More
Novel Antibiotics for Resistant Pathogens: Results of ATTACK Trial for Sulbactam-Durlobactam
April 26th 2022Entasis Therapeutics gave 2 oral presentations at ECCMID today detailing results of their ATTACK trial, investigating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) for multidrug-resistant pathogens.
Read More
Longer Intervals Between COVID-19 Vaccine Doses Leads to Higher Antibody Levels
April 25th 2022One study, presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), found waiting longer in between the first and second Pfizer-BioNTech vaccine doses boosted immune response 9-fold.
Read More
Shionogi’s Oral Antiviral S-217622 Rapidly Clears COVID-19 Virus
April 23rd 2022Today at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Shionogi presented late-breaking data from their phase 2/3 clinical trial for S-217622, an investigational 3CL protease inhibitor. On day 4 of treatment with Shionogi’s S-217622, COVID-19 positive viral titers decreased by 90%.
Read More
Testing Procalcitonin Levels to Guide Antimicrobial Stewardship
April 21st 2022Investigators used procalcitonin (PCT) levels to guide antibiotic recommendations in pediatric intensive care units. PCT-guided antibiotic stewardship decreased the number of antibiotic days without leading to therapy failure.
Read More
Identifying High-Risk Recurrent Clostridioides Difficile Patients for Bezlotoxumab
April 18th 2022The greatest risk factors for recurrent Clostridioides difficile infection (CDI) were age of at least 65 years, severe primary CDI, and use of non-CDI antibiotics. Patients with these risk factors should be prioritized for bezlotoxumab therapy.
Read More
Fidaxomicin Versus Vancomycin for Clostridioides Difficile Treatment
April 15th 2022Concomitant antibiotic (CA) use for infection treatment is a major risk factor for recurrent C difficile infection. One SHEA 2022 study examined whether fidaxomicin or vancomycin would be more beneficial for CA patients.
Read More